Dose-related modulation of event-related potentials to novel and target stimuli by intravenous δ 9-THC in humans

Neuropsychopharmacology

Volumn 37, Issue 7, 2012, Pages 1632-1646

  D'Souza, Deepak Cyril ^a,b,c   Fridberg, Daniel J ^a   Skosnik, Patrick D ^a,b,c   Williams, Ashley ^a,b,c   Roach, Brian ^c,d   Singh, Nagendra ^a,b,c   Carbuto, Michelle ^a,b,c   Elander, Jacqueline ^a,b,c   Schnakenberg, Ashley ^a,b,c   Pittman, Brian ^b,c   Sewell, R Andrew ^a,b,c   Ranganathan, Mohini ^a,b,c   Mathalon, Daniel ^c,d  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

9 THC; cannabinoids; cannabis; P300; perception; psychosis

Indexed keywords

CANNABIS; DRONABINOL; PSYCHEDELIC AGENT;

ARTICLE; ATTENTION; AUDITORY STIMULATION; BEHAVIOR; BLOOD SAMPLING; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; NORMAL HUMAN; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ATTENTION; CEREBRAL CORTEX; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; REACTION TIME; TETRAHYDROCANNABINOL;

EID: 84861194647     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.8     Document Type: Article

References (93)

1. Ali AB, Todorova M (2010). Asynchronous release of GABA via tonic cannabinoid receptor activation at identified interneuron synapses in rat CA1. Eur J Neurosci 31: 1196-1207.
2. Azorlosa JL, Greenwald MK, Stitzer ML (1995). Marijuana smoking: effects of varying puff volume and breathhold duration. J Pharmacol Exp Ther 272: 560-569.
3. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992). Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261: 114-122.
4. Bacci A, Huguenard JR, Prince DA (2004). Long-lasting selfinhibition of neocortical interneurons mediated by endocannabinoids. Nature 431: 312-316. (Pubitemid 39265666)
5. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T et al (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
6. Blackwood DH, Whalley LJ, Christie JE, Blackburn IM, St Clair DM, McInnes A (1987). Changes in auditory P3 event-related potential in schizophrenia and depression. Br J Psychiatry 150: 154-160. (Pubitemid 17010728)
7. Bocker KB, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL (2010). Cannabis with high delta9-THC contents affects perception and visual selective attention acutely: an event-related potential study. Pharmacol Biochem Behav 96: 67-74.
8. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N et al (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845-6856. (Pubitemid 41023152)
9. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Traum Stress 11: 125-136. (Pubitemid 28097797)
10. Brunner E, Domhof S, Langer F (2002). Nonparametric Analysis of Longitudinal Data in Factorial Experiments. John Wiley & Sons: New York, NY. .
11. Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J et al (2011). The safety of studies with intravenousDelta(9)- tetrahydrocannabinol in humans, with case histories. Psychopharmacology (Berl) 219: 885-896.
12. Clarke JM, Halgren E, Chauvel P (1999). Intracranial ERPs in humans during a lateralized visual oddball task: I. occipital and peri-rolandic recordings. Clin Neurophysiol 110: 1210- 1225.
13. Cohen J (1973). Eta-squared and partial Eta-squared in communication science. Hum Comm Res 28: 473-490.
14. Coull JT (1998). Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 55: 343-361. (Pubitemid 28255041)
15. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B et al (2008a). Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 198: 587-603.
16. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572. (Pubitemid 38982249)
17. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T et al (2008b). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33: 2505-2516.
18. de Sola S, Tarancon T, Pena-Casanova J, Espadaler JM, Langohr K, Poudevida S et al (2008). Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study. Psychopharmacology (Berl) 200: 425-437.
19. Doherty J, Dingledine R (2003). Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 3: 46-53. (Pubitemid 36131326)
20. Donchin E, Coles M (1988). Is the P300 component a manifestation of context updating? (Commentary on Verleger's critique of the context updating model). Behav Brain Sci 11: 357-374.
21. Duncan-Johnson CC, Donchin E (1977). On quantifying surprise: the variation in event-related potentials with subjective probability. Psychophysiology 14: 456-467. (Pubitemid 8190202)
22. Egan MF, Duncan CC, Suddath RL, Kirch DG, Mirsky AF, Wyatt RJ (1994). Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr Res 11: 259-271. (Pubitemid 24063746)
23. Eggan SM, Lewis DA (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175-191. (Pubitemid 44973906)
24. Eggan SM, Melchitzky DS, Sesack SR, Fish KN, Lewis DA (2010). Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 169: 1651-1661.
25. Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T (2001). The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 11: 728-733. (Pubitemid 32718077)
26. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders- Non-patient Edition. American Psychiatric Association: Washington, DC. .
27. Foldy C, Neu A, Jones MV, Soltesz I (2006). Presynaptic, activitydependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci 26: 1465-1469. (Pubitemid 43237017)
28. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R et al (1998). Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J Addict Dis 17: 23-34. (Pubitemid 28156155)
29. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066. (Pubitemid 36828930)
30. Friedman D, Simpson G, Hamberger M (1993). Age-related changes in scalp topography to novel and target stimuli. Psychophysiology 30: 383-396. (Pubitemid 23184744)
31. Frodl-Bauch T, Bottlender R, Hegerl U (1999). Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology 40: 86-94. (Pubitemid 29410826)
32. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77: 299-318. (Pubitemid 27079604)
33. Gratton G, Coles MG, Donchin E (1983). A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol 55: 468-484. (Pubitemid 13112654)
34. Grotenhermen F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42: 327-360. (Pubitemid 36433875)
35. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M et al (2005). Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 25: 8593-8600. (Pubitemid 41362035)
36. Halgren E, Marinkovic K, Chauvel P (1998). Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol 106: 156-164. (Pubitemid 28133396)
37. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999). Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 141: 385-394. (Pubitemid 29190007)
38. Hart CL, Ilan AB, Gevins A, Gunderson EW, Role K, Colley J et al (2010). Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacol Biochem Behav 96: 333-341.
39. Higashima M, Urata K, Kawasaki Y, Maeda Y, Sakai N, Mizukoshi C et al (1998). P300 and the thought disorder factor extracted by factor-analytic procedures in schizophrenia. Biol Psychiatry 44: 115-120. (Pubitemid 28305530)
40. Hill EL, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P et al (2007). Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol 97: 2580-2589. (Pubitemid 46557693)
41. Hillyard SA, Hink RF, Schwent VL, Picton TW (1973). Electrical signs of selective attention in the human brain. Science 182: 177-180.
42. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C et al (2011). Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry; e-pub ahead of print 12 July 2011.
43. Ilan AB, Gevins A, Coleman M, Elsohly MA, de Wit H (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 16: 487-496. (Pubitemid 41404822)
44. Ilan AB, Smith ME, Gevins A (2004). Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berl) 176: 214-222. (Pubitemid 39517951)
45. Javitt DC, Schroeder CE, Steinschneider M, Arezzo JC, Ritter W, Vaughan Jr HG (1995). Cognitive event-related potentials in human and non-human primates: implications for the PCP/ NMDA model of schizophrenia. Electroencephalogr Clin Neurophysiol Suppl 44: 161-175.
46. Jeon YW, Polich J (2003). Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40: 684-701. (Pubitemid 37128034)
47. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al (2000). GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100: 797-804.
48. Kawasaki Y, Maeda Y, Sakai N, Higashima M, Urata K, Yamaguchi N et al (1994). Evaluation and interpretation of symptom structures in patients with schizophrenia. Acta Psychiatr Scand 89: 399-404. (Pubitemid 24210084)
49. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry (Suppl 7): 59-67.
50. Kempel P, Lampe K, Parnefjord R, Hennig J, Kunert HJ (2003). Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiology 48: 95-101. (Pubitemid 37176874)
51. Kiehl KA, Laurens KR, Duty TL, Forster BB, Liddle PF (2001). Neural sources involved in auditory target detection and novelty processing: an event-related fMRI study. Psychophysiology 38: 133-142. (Pubitemid 32154953)
52. Knight R (1996). Contribution of human hippocampal region to novelty detection. Nature 383: 256-259. (Pubitemid 26317674)
53. Knight RT (1984). Decreased response to novel stimuli after prefrontal lesions in man. Electroencephalogr Clin Neurophysiol 59: 9-20. (Pubitemid 14128147)
54. Knight RT, Scabini D (1998). Anatomic bases of event-related potentials and their relationship to novelty detection in humans. J Clin Neurophysiol 15: 3-13. (Pubitemid 29090719)
55. Kramer AF, Strayer DL (1988). Assessing the development of automatic processing: an application of dual-task and eventrelated brain potential methodologies. Biol Psychol 26: 231-267. (Pubitemid 19009430)
56. Lichtman AH, Martin BR (2005). Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168: 691-717.
57. Luck SJ, Mathalon DH, O'Donnell BF, Hamalainen MS, Spencer KM, Javitt DC et al (2011). A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry 70: 28-34.
58. Lundqvist T (2005). Cognitive conseq uences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav 81: 319-330. (Pubitemid 40807130)
59. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M (2001). Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31: 463-475. (Pubitemid 32778564)
60. Marti F, Arib O, Morel C, Dufresne V, Maskos U, Corringer PJ et al (2011). Smoke extracts and nicotine, but not tobacco extracts, potentiate firing and burst activity of ventral tegmental area dopaminergic neurons in mice. Neuropsychopharmacology 36: 2244-2257.
61. Mathalon DH, Ford JM, Pfefferbaum A (2000). Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 47: 434-449. (Pubitemid 30110615)
62. Mathalon DH, Hoffman RE, Watson TD, Miller RM, Roach BJ, Ford JM (2010). Neurophysiological distinction between schizophrenia and schizoaffective disorder. Front Hum Neurosci 3: 70.
63. McCarthy G, Donchin E (1981). A metric for thought: a comparison of P300 latency and reaction time. Science 211: 77-80. (Pubitemid 11148488)
64. Mereu G, Fa M, Ferraro L, Cagiano R, Antonelli T, Tattoli M et al (2003). Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal longterm potentiation and glutamate release. Proc Natl Acad Sci USA 100: 4915-4920. (Pubitemid 36457828)
65. Merrin EL, Floyd TC (1994). P300 responses to novel auditory stimuli in hospitalized schizophrenic patients. Biol Psychiatry 36: 527-542. (Pubitemid 24330631)
66. Nieuwenhuis S, Aston-Jones G, Cohen JD (2005). Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol Bull 131: 510-532. (Pubitemid 41168494)
67. ONDCP, O. o. N. D. C. P. (2008). Marijuana: The Greatest Cause of Illegal Drug Abuse. The Marijuana Factbook. Executive Office of the President: Washington, DC. 20503.
68. Patrick G, Straumanis JJ, Struve FA, Fitz-Gerald MJ, Manno JE (1997). Early and middle latency evoked potentials in medically and psychiatrically normal daily marihuana users: a paucity of significant findings. Clin Electroencephal 28: 26-31. (Pubitemid 27045411)
69. Patrick G, Straumanis JJ, Struve FA, Nixon F, Fitz-Gerald MJ, Manno JE et al (1995). Auditory and visual P300 event related potentials are not altered in medically and psychiatrically normal chronic marihuana users. Life Sciences 56: 2135-2140.
70. Polich J (1989). Habituation of P300 from auditory stimuli. Psychobiology 17: 19-28.
71. Polich J (2007). Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol 118: 2128-2148. (Pubitemid 47385341)
72. Polich J, Criado JR (2006). Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol 60: 172-185. (Pubitemid 43776735)
73. Porjesz B, Rangaswamy M, Kamarajan C, Jones KA, Padmanabhapillai A, Begleiter H (2005). The utility of neurophysiological markers in the study of alcoholism. Clin Neurophysiol 116: 993-1018.
74. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23: 266-277.
75. Ranganathan M, D'Souza DC (2006). The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 188: 425-444. (Pubitemid 44498214)
76. Ray PG, Meador KJ, Loring DW (1992). Diazepam effects on the P3 event-related potential. J Clin Psychopharmacol 12: 415-419.
77. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM (2008). Effects of acute oral Delta(9)-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18: 569-577.
78. Saitoh O, Niwa S, Hiramatsu K, Kameyama T, Rymar K, Itoh K (1984). Abnormalities in late positive components of eventrelated potentials may reflect a genetic predisposition to schizophrenia. Biol Psychiatry 19: 293-303. (Pubitemid 14130667)
79. SAMHSA, (2011). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental Health Services Administration: Rockville, MD. .
80. Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC (2010). Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia. Rev Bras Psiquiatr 32(Suppl 1): S15-S30.
81. Shaw LM, Edling-Owens J, Mattes R (1991). Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry. Clin Chem 37: 2062-2068. (Pubitemid 21925901)
82. Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O'Donnell BF (2006). Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry 163: 1798-1805. (Pubitemid 44522490)
83. Skosnik PD, Park S, Dobbs L, Gardner WL (2008). Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry Res 157: 279-282. (Pubitemid 350166545)
84. Solowij N, Michie PT, Fox AM (1991). Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40: 683-688.
85. Solowij N, Michie PT, Fox AM (1995). Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37: 731-739.
86. Soltani M, Knight RT (2000). Neural origins of the P300. Crit Rev Neurobiol 14: 199-224. (Pubitemid 36292455)
87. St Clair D, Blackwood D, Muir W (1989). P300 abnormality in schizophrenic subtypes. J Psychiatr Res 23: 49-55. (Pubitemid 19191583)
88. Stadelmann AM, Juckel G, Arning L, Gallinat J, Epplen JT, Roser P (2011). Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neurosci Lett 496: 60-64.
89. Turetsky BI, Fein G (2002). Alpha2-noradrenergic effects on ERP and behavioral indices of auditory information processing. Psychophysiology 39: 147-157. (Pubitemid 34263251)
90. Verleger R, Jaskowski P, Wascher E (2005). Evidence for an integrative role of P3b in linking reaction to perception. J Psychophysiol 19: 165-181. (Pubitemid 41051851)
91. Villares J (2007). Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145: 323-334. (Pubitemid 46237689)
92. Wang SJ (2003). Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes. Eur J Pharmacol 469: 47-55.
93. Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH (2009). Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. Int J Neuropsychopharmacol 12: 357-370.